Non-alcoholic Steatohepatitis (NASH)

Global Market Trajectory & Analytics

MCP16633

EXECUTIVE ENGAGEMENTS

POOL

523
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

103
Interactions with Platform & by Email

PARTICIPANTS

21
Unique # Participated

VALIDATIONS

9
Responses Validated*

COMPANIES

10
Responses Validated*
* Login for a full stack data experience

DATE

APR 2021

TABLES

108

PAGES

148

EDITION

5

PRICE

USD 5450

CODE

MCP16633


COMPETITIVE METRICS

COMPANY

D S N T

% *

89bio

Akero Therapeutics

AstraZeneca PLC

Avaliv Therapeutics

BioVie

Caldan Therapeutics

Cirius Therapeutics

Conatus Pharmaceuticals Inc.

ConSynance Therapeutics

Galmed Pharmaceuticals Ltd.

View More...

SUBMIT
Note: Best viewed in Landscape Mode
  

HIGHLIGHTS & REPORT INDEX

Amid the COVID-19 crisis, the global market for Non-alcoholic Steatohepatitis (NASH) estimated at US$2 Billion in the year 2020, is projected to reach a revised size of US$39.5 Billion by 2027, growing at a CAGR of 53.2% over the analysis period 2020-2027. Vitamin E & Pioglitazone, one of the segments analyzed in the report, is projected to record a 46.1% CAGR and reach US$16.5 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Obeticholic Acid (OCA) segment is readjusted to a revised 44.4% CAGR for the next 7-year period.
The Non-alcoholic Steatohepatitis (NASH) market in the U.S. is estimated at US$606.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$6.4 Billion by the year 2027 trailing a CAGR of 50.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 46.5% and 45.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 35.5% CAGR.
In the global Elafibranor segment, USA, Canada, Japan, China and Europe will drive the 72.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$208.6 Million in the year 2020 will reach a projected size of US$9.6 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$5 Billion by the year 2027.

SELECT PLAYERS

AstraZeneca PLC; Conatus Pharmaceuticals Inc.; Galmed Pharmaceuticals Ltd.; Genfit SA; Gilead Sciences, Inc.; Immuron Ltd.; Intercept Pharmaceuticals, Inc.; Zydus Cadila

SEGMENTS

» Drug Type (Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor, Selonsertib & Cenicriviroc) » Sales Channel (Hospital Pharmacy, Online Provider, Retail Pharmacy)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Non-alcoholic Steatohepatitis (NASH) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
World Current & Future Analysis for Vitamin E & Pioglitazone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Vitamin E & Pioglitazone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Vitamin E & Pioglitazone by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Obeticholic Acid (OCA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Obeticholic Acid (OCA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Obeticholic Acid (OCA) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Elafibranor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Elafibranor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Elafibranor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Selonsertib & Cenicriviroc by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Selonsertib & Cenicriviroc by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Selonsertib & Cenicriviroc by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Online Provider by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Online Provider by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Online Provider by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
UNITED STATES
USA Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years 2012, 2020 & 2027
USA Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Online Provider and Retail Pharmacy for the Years 2012, 2020 & 2027
CANADA
Canada Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years 2012, 2020 & 2027
Canada Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Online Provider and Retail Pharmacy for the Years 2012, 2020 & 2027
JAPAN
Japan Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years 2012, 2020 & 2027
Japan Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Online Provider and Retail Pharmacy for the Years 2012, 2020 & 2027
CHINA
China Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years 2012, 2020 & 2027
China Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Online Provider and Retail Pharmacy for the Years 2012, 2020 & 2027
EUROPE
Europe Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Europe Historic Review for Non-alcoholic Steatohepatitis (NASH) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
Europe Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years 2012, 2020 & 2027
Europe Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Online Provider and Retail Pharmacy for the Years 2012, 2020 & 2027
FRANCE
France Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years 2012, 2020 & 2027
France Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Online Provider and Retail Pharmacy for the Years 2012, 2020 & 2027
GERMANY
Germany Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years 2012, 2020 & 2027
Germany Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Online Provider and Retail Pharmacy for the Years 2012, 2020 & 2027
ITALY
Italy Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years 2012, 2020 & 2027
Italy Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Online Provider and Retail Pharmacy for the Years 2012, 2020 & 2027
UNITED KINGDOM
UK Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years 2012, 2020 & 2027
UK Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Online Provider and Retail Pharmacy for the Years 2012, 2020 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years 2012, 2020 & 2027
Rest of Europe Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Online Provider and Retail Pharmacy for the Years 2012, 2020 & 2027
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Online Provider and Retail Pharmacy for the Years 2012, 2020 & 2027
REST OF WORLD
Rest of World Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years 2012, 2020 & 2027
Rest of World Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Online Provider and Retail Pharmacy for the Years 2012, 2020 & 2027
Total Companies Profiled: 10

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com